@article{4eeb175e18ed4b40aebc6cd9ac952163,
title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update",
abstract = " The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC {\textregistered} ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).",
author = "Ursula Amstutz and Henricks, {Linda M.} and Offer, {Steven M.} and Julia Barbarino and Schellens, {Jan H.M.} and Swen, {Jesse J.} and Klein, {Teri E.} and McLeod, {Howard L.} and Caudle, {Kelly E.} and Diasio, {Robert B.} and Matthias Schwab",
note = "Funding Information: We acknowledge the critical input of members of CPIC of the Pharmacogenomics Research Network (PGRN), particularly Dr. Mary V. Relling (St Jude Children{\textquoteright}s Research Hospital) funded by the National Institutes of Health (NIH). This work was funded by the NIH for CPIC (R24GM115264) and PharmGKB (R24GM61374). This work is also supported by the Robert Bosch Foundation, Stuttgart, Germany. CPICVR is a registered service mark of the U.S. Department of Health & Human Services (HHS). Funding Information: We acknowledge the critical input of members of CPIC of the Pharmacogenomics Research Network (PGRN), particularly Dr. Mary V. Relling (St Jude Children's Research Hospital) funded by the National Institutes of Health (NIH). This work was funded by the NIH for CPIC (R24GM115264) and PharmGKB (R24GM61374). This work is also supported by the Robert Bosch Foundation, Stuttgart, Germany. CPIC is a registered service mark of the U.S. Department of Health & Human Services (HHS). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision making and to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. Guidelines are limited in scope and are not applicable to interventions or diseases that are not specifically identified. Guidelines do not account for individual variations among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the healthcare provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. CPIC assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of CPIC's guidelines, or for any errors or omissions. Publisher Copyright: {\textcopyright} 2017 American Society for Clinical Pharmacology and Therapeutics",
year = "2018",
month = feb,
doi = "10.1002/cpt.911",
language = "English (US)",
volume = "103",
pages = "210--216",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",
}